多烯磷脂酰胆碱联合干扰素α治疗慢性乙型肝炎

目的：探讨多烯磷脂酰胆碱（PPC，易善复）联合干扰素α治疗HBeAg阴性慢性乙型肝炎的疗效。方法：将80例患者随机分成治疗组60例和对照组20例，前者采用PPC联合干扰素α治疗24周，后者同期仅采用干扰素仅治疗，对照观察两组疗程结束时免疫应答及随访24周时持续应答情况。结果：治疗组和对照组疗程结束时免疫应答数分别为46（76．67％），8（40．00％），χ^2=9．193，P〈0．01；两组随访24周末持续应答数分别为40（66．67％），6（30．00％），χ^2=8．252，P〈0．01，两组具有显著性差异。结论：采用PPC联合干扰素α治疗HBeAg阴性慢性乙型肝炎近期疗效优于单用干扰素α，值得临床推广应用。

Clinical Observation of the Treatment of HBeAg Negative Chronic Hepatitis B with PPC and Interferon Alpha

Objective:To discuss the curative effect of the treatment of the HBeAg by using PPC combined with interferon a. Method: 80 patients were randomly divided into a group of 60 patients and a group of 20 patients. The former group was administered with PPC together with interferon a for 24 weeks. Meanwhile, the latter were administered only with interferon a. When the treatment ended, the immunity response of the two groups continued to be observed and visited for 24 weeks. Result: The parameters for immunity response were 46(76.67%) and 8(40.00%) respectively,x2=9.193,P<0.01;the parameters for continuous response were 40(66.67%)and 6(30.00%) respectively,x2=8.252, P<0.01. There were distinct differences in the results. Conclusion:The recent curative effect of the treatment of the HBeAg by using PPC combined with interferon a is better than that by using interferon a separately and the method deserves spreading.